Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2013 | 10:15am CET

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
www.drreddys.com

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

Media:
S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR.REDDY'S LABORATORIES LT
01/19 INDIAN ADRS : ICICI Bank, Tata Motors rise; Wipro falls
01/13 DR REDDY LABORATORIES : USFDA TO RE-AUDIT Dr REDDY'S THREE PLANTS
01/12 DR REDDY LABORATORIES : Plants of Pharma major, Dr. Reddy's to be re-audited by ..
01/11 DR. REDDY'S LABORATORIES LIMITED : to present at the J.P. Morgan 35th Annual Hea..
01/09 DR REDDY LABORATORIES : to Present at the J.P. Morgan 35th Annual Healthcare Con..
01/09 Live Stock Market Updates - Sensex, Nifty trade flat; FMCG, Metal stocks lead
01/06 DR REDDY LABORATORIES : Helps women get back on the career beat
2016 ET500-2016 RANKINGS : Dr reddy's laboratories limited
2016 DR REDDY LABORATORIES : `s launches antifungal skin cream in US
2016 DR REDDY LABORATORIES : Anti-fungal cream in us
More news
Sector news : Pharmaceuticals - NEC
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/10 Dr. Reddy's launches two new generics in U.S.
2016 A Somewhat Murky Outlook For Momenta Pharmaceuticals
2016 New Oral Psoriasis Drug Tops Cellceutix Catalysts
2016 Dr. Reddy's launches generic topical creams in U.S.
2016 Vantage Point - Going Small To Hit It Big
Advertisement
Financials ( INR)
Sales 2017 148 446 M
EBIT 2017 18 993 M
Net income 2017 15 809 M
Debt 2017 12 655 M
Yield 2017 0,62%
P/E ratio 2017 32,01
P/E ratio 2018 20,85
EV / Sales 2017 3,47x
EV / Sales 2018 2,98x
Capitalization 502 026 M
More Financials
Chart DR.REDDY'S LABORATORIES LT
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 44
Average target price 3 166  INR
Spread / Average Target 7,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DR.REDDY'S LABORATORIE..-3.63%7 368
JOHNSON & JOHNSON-0.88%310 685
ROCHE HOLDING LTD.1.29%200 208
PFIZER INC.-2.40%192 367
NOVARTIS AG-3.71%185 489
MERCK & CO., INC.2.48%166 338
More Results